In 2016, the American Academy of Pediatrics called on healthcare providers to prescribe medications for opioid use disorder to adolescents and young adults. Recent data reflect a modest increase in young people receiving treatments like buprenorphine and methadone; however, the persistence of these patients in treatment has not improved, and may even be declining.
Scott Hadland, chief of adolescent and young adult medicine at Mass General Brigham for Children, commented, “There have been some real positive changes, and then there have been some really catastrophic changes.” His recent study, published in JAMA Network Open, highlights the ongoing challenges in the continuum of care for young people diagnosed with opioid use disorder.
Analyzing claims and Medicaid data for those aged 13 to 25 from 2016 to 2023, the research found that out of nearly 230,000 youth diagnosed, about half initiated treatment. However, only one in six received medication within that initial period, and a dismal one in thirty-two remained on treatment for six months. As overdose deaths surged among this demographic starting in 2019, opioid-related poisonings ranked as the third leading cause of death for people under 19.
“I have had patients die as recently as this past month here in Massachusetts, from overdose,” Hadland noted, emphasizing the seriousness of the situation. Despite the effectiveness and affordability of medications like buprenorphine and methadone, hurdles remain significant, especially for minors. For example, federal regulations require adolescents to provide proof of failed recovery attempts before accessing methadone, and many clinics do not accept minors at all.
Buprenorphine presents a more accessible option, but recent studies suggest that many residential treatment facilities for youths do not offer it. “Once you turn 18, a whole bigger field of people are open to helping you,” stated Sivabalaji Kaliamurthy, a child and adolescent psychiatrist. This limitation restricts the support available to younger patients.
In Hadland's research, the number of adolescents prescribed methadone was notably low—less than ten in a seven-year span—resulting in confidentiality issues for the researchers. Despite numerous studies affirming the safety and efficacy of these medications, a lack of conclusive research specifically targeting young people leaves healthcare providers unable to provide comprehensive guidance about the duration or long-term impacts of medication.
As Kaliamurthy remarked, young individuals often resist the notion of long-term treatment, and families also grapple with the commitment involved. The study also identified disparities in care retention rates, with Black and minoritized youth experiencing higher dropout rates compared to their white counterparts.
Kaliamurthy acknowledged the potential in the rising number of youth seeking treatment but underscored the imperative to enhance retention strategies. “It doesn’t matter how good the treatment we have actually is if we haven’t created a clinical environment that is appealing, safe, compassionate, and nonjudgmental,” pointed out Sarah Bagley, a pediatrician and internist at Boston Medical Center. She emphasized that the engagement aspect of treatment is paramount for success.
Bagley advocates for continued research focused on the unique needs of young people since their circumstances differ significantly from adults. The necessity for primary care providers and pediatricians to feel capable and supported in prescribing buprenorphine is becoming apparent, and interest in understanding opioid use disorder seems to be growing among general practitioners.
Hadland has observed a cultural shift; medical professionals are increasingly recognizing the need for thorough education about addiction treatment for young people. On the day his study was released, he was tasked with delivering a keynote address at the American Academy of Pediatrics' annual conference on the pressing issues of addiction and the increasing potency of opioid drugs. His experience underlines a broader movement toward equipping healthcare professionals to better address youth substance use issues.
As experts continue to dissect the effectiveness of existing treatment frameworks, it is clear that the healthcare community must shift its focus to ensure comprehensive care that keeps young patients engaged in their recovery process. Through empathetic and informed practices, there remains hope for improving retention rates and better outcomes for youth confronting the challenges of opioid addiction.
STAT’s coverage of chronic health issues is supported by a grant from Bloomberg Philanthropies. Our financial supporters are not involved in any decisions about our journalism.